Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Beverly Hills, California 90210


The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.


Inclusion Criteria: - Male and female healthy volunteer subjects, between 25 and 70 years of age, giving informed consent for facial laser ablation of the lower eyelid areas for the purpose of wrinkle removal. - Lower eyelid skin is free of any irritation, scarring or dermatologic conditions which might interfere with the study. - Willing and able to participate in the study and follow all study directions. - Able to read, understand and sign the consent form prior to any study related procedures. Exclusion Criteria: - Female subjects who are pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test. - Presence of irritation or dermatologic skin conditions in the lower eyelid area. - Known allergies to materials within the test formulations (i.e., yeast and/or yeast products). - Use of topical or systemic drugs (corticosteroids, retinoids, immune modulators, immune suppressants, drugs with potential for contact dermatitis, drugs with potential for skin discoloration) that may have an effect on wound healing or may impact skin pigmentation. - A history, upon wounding, of developing thickened scars, keloids, or excessive pigment change. - An unstable or severe inter-current medical condition that, in the opinion of the investigator, might interfere with interpretation of study results or render the subject at high risk for treatment complications. - Use of any investigational medication or device for any indication within 30 days of screening.



Primary Contact:

Principal Investigator
John Joseph, MD
The Clinical Testing Center of Beverly Hills

Backup Contact:


Location Contact:

Beverly Hills, California 90210
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.